Best Wound Care Companies in United States
The 307 best Wound Care companies in United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MiMedx Group.
Ranked by disclosed equity funding and recent momentum, the 307 Wound Care companies we track across the United States have pulled in $1.7B in total disclosed funding, with no unicorns yet but a clear concentration of capital at the top. Cresilon leads at $82M, followed by Nuo Therapeutics at $65M and Imbed Biosciences at $34M. That's a tight funding cluster, and it tells you something: this is still a sector where institutional backers like NIH, the National Science Foundation, and Military Health are doing a lot of the heavy lifting alongside private capital.
The underlying market gives those bets real foundation. Global wound care sits at roughly $28.0B and is forecast to reach $29.6B by 2030 at a 5.2% CAGR, driven by aging populations, rising surgical volumes, and the grinding prevalence of chronic disease. Regulatory hurdles remain the friction point, slowing smaller innovators even as self-healing hydrogel technology signals what the next product generation could look like. So if you're evaluating where the real commercial traction is building, the funding distribution here is your clearest signal.
- Wound Care Market to Hit $24 Billion by 2027
- [Latest Report] Wound Care Market is estimated to be US$ 37.15 billion
Ranked: Best Wound Care companies in United States
| # | Company | Disclosed funding | Last round | Employees | Founded | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | MiMedx Group Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics | $213M | 71 mo ago | 735 735 → 789 (+7%) | 1985 | 6 signals ▼40% Earnings · Leadership | 472 patents Placental-derived collagen wound healing matrices and grafts for tissue repair | 1 launch |
| 2 | BioTissue Developer of regenerative biologic therapies for eye care | $110M | 59 mo ago | 234 234 → 372 (+59%) | 2001 | — | 31 patents Patents concentrated in health & consumer products | 1 job opening |
| 3 | Cresilon Developer of hemostatic products for wound care 60Funding top 22%Growth top 32%Moat top 32%Product top 35% All 10 signals ▾Fundingtop 22% Growthtop 32% Moattop 32% Producttop 35% Techtop 37% Patentstop 42% Innovationtop 48% Marketbottom 46% Globalbottom 36% Newsbottom 18% Funding: Raised $81.7M across 8 rounds · 8 rounds over 10 yrs (0.8/yr) Growth: Headcount 53 → 73 (+38%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $82M | 1 mo ago | 73 | 2010 | — | 40 patents Hemostatic polymer adhesives and delivery devices for rapid surgical bleeding control | — |
| 4 | CoDa Therapeutics Developer of therapeutics for wound care and tissue repair | $78M | 120 mo ago | — | 2007 | — | 187 patents Connexin-targeted therapeutics and antisense oligonucleotide treatments for ocular and wound healing | — |
| 5 | Celleration MIST Ultrasound based wound healing therapy | $71M | 161 mo ago | 43 | 1999 | — | 36 patents Ultrasonic wound therapy devices and applicators for medical wound healing | — |
| 6 | Nuo Therapeutics Developer of regenerative products for wound care 53Growth top 11%Funding top 24%Talent top 45%Fin. health top 50% All 9 signals ▾Growthtop 11% Fundingtop 24% Talenttop 45% Fin. healthtop 50% Moatbottom 38% Globalbottom 37% Marketbottom 33% Techbottom 30% Newsbottom 21% Growth: Revenue +143% YoY · Fresh capital in last 24 mo Funding: Raised $64.6M across 18 rounds · 18 rounds over 16 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $65M | 10 mo ago | 10 10 → 19 (+90%) | 2001 | — | — | — |
| 7 | Spiracur Wound healing device based on negative pressure therapy | $55M | 139 mo ago | 48 | 2007 | — | 102 patents Patents concentrated in health & consumer products | — |
| 8 | RedDress Provider of dressing solution for wound care | $43M | 36 mo ago | 31 | 2009 | — | — | — |
| 9 | Imagine Pharma Developing polypeptide therapeutic drugs for treating cardiovacular disorders | $40M | 31 mo ago | 12 | 2016 | — | — | — |
| 10 | Solsys Medical Provider of human skin allograft and dressing for wound care | $37M | 103 mo ago | 80 | 1999 | — | — | — |
| 11 | Imbed Biosciences Provider of nanotech-based wound care products 48Growth top 32%Funding top 37%Talent top 38%Moat top 39% All 7 signals ▾Growthtop 32% Fundingtop 37% Talenttop 38% Moattop 39% Techtop 44% Marketbottom 33% Globalbottom 32% Growth: Headcount 24 → 35 (+46%) across vintages · Fresh capital in last 24 mo Funding: Raised $34.3M across 18 rounds · 18 rounds over 16 yrs (1.1/yr) rank vs industry peers · Fliar Intelligence Index 48/100 | $34M | 4 mo ago | 35 35 → 40 (+14%) | 2010 | — | — | — |
| 12 | Triad Life Sciences Developer of regenerative medicine technologies | $32M | 57 mo ago | 33 | 2017 | — | — | — |
| 13 | EO2Concepts Developer of continuous diffusion of oxygen (CDO) therapy based devices | $31M | 43 mo ago | 40 | 2007 | — | — | — |
| 14 | Organogenesis Regenerative tissue innovations for advanced wound care and surgical solutions | $30M | 19 mo ago | 856 856 → 921 (+8%) | 1985 | 7 signals ▼73% Earnings | 209 patents Collagen-based biomaterials for wound healing, tissue regeneration, and anti‑inflammatory assay kits. | — |
| 15 | Marizyme Developer of therapy for the treatment of chronic wounds, thrombolysis, and dental health | $30M | 37 mo ago | 11 | 2007 | — | 21 patents Pharmaceutical powder and preservation formulations for surgical and organ transplantation use | — |
| 16 | Tricol Biomedical Hemostasis and wound-care innovator dedicated to saving lives | $26M | 56 mo ago | 24 | 2001 | — | 48 patents Chitosan-based hemostatic and tissue‑adhesive medical devices for surgical bleeding control | — |
| 17 | Reprise Biomedical Developer of surgical mesh for wound management | $23M | 1 mo ago | 16 | 2019 | — | — | — |
| 18 | Stemson Therapeutics Developer of stem cell based therapy for hair growth | $22M | 59 mo ago | 31 | 2019 | — | — | — |
| 19 | Kitotech Medical Developer of a device to close wounds, lacerations, and surgical incisions | $21M | 24 mo ago | 16 | 2011 | — | — | — |
| 20 | Tempo Therapeutics Developer of regenerative biomaterials for wounds | $20M | 16 mo ago | 15 | 2014 | — | — | — |
| 21 | ULURU Medical technology company innovating wound care and drug delivery systems | $20M | 78 mo ago | 5 | 1987 | — | 47 patents Advanced biomedical hydrogels and polymeric nanoparticle drug delivery formulations | — |
| 22 | Royal Biologics Innovating orthobiologics and wound care solutions for enhanced healing | $20M | 16 mo ago | 16 | 2015 | — | 14 patents Autologous bone graft enhancement and marrow-derived cell/fluid separation technologies. | 2 launchs |
| 23 | Encellin Developer of regenerative materials | $18M | 32 mo ago | 9 | 2015 | — | 18 patents Implantable cell encapsulation systems with pre‑vascularization for therapeutic drug/device delivery. | — |
| 24 | SweetBio Developer of wound-healing therapies for oral surgery | $17M | 42 mo ago | 7 | 2015 | — | 2 patents Biomaterial compositions for bone and soft tissue regeneration therapies | 2 partnerships |
| 25 | Mosaic Biosciences Protein and antibody therapeutics discovery from concept to clinical candidate | $15M | 48 mo ago | 36 | 2009 | — | — | — |
| 26 | Adhezion Biomedical Developer of cyanoacrylate based surgical, wound management, and infection prevention products | $13M | 65 mo ago | 39 39 → 52 (+33%) | 2001 | — | 134 patents Patents concentrated in health & consumer products | — |
| 27 | Scarless Laboratories Developer of therapies for scar minimization and wound healing | $13M | 56 mo ago | — | 2004 | — | — | — |
| 28 | Omeza Discovering and developing solutions for closing chronic wounds and preventing their recurrence | $13M | 1 mo ago | 22 | 2005 | — | 10 patents Topical marine oil formulations for wound healing and dermatological therapy | — |
| 29 | Advanced Oxygen Therapy Develops solutions for the treatment of severe acute and chronic wounds | $12M | 50 mo ago | 62 | 2004 | — | — | — |
| 30 | Guard Medical Developer of smart wound dressing products for wound care | $11M | 50 mo ago | 9 | 2018 | — | — | — |
| 31 | GeniPhys Developer of collagen polymers for tissue regeneration | $10M | 4 mo ago | 4 | 2014 | — | 18 patents Collagen-based biologic fillers for tissue regeneration and high-strength matrix scaffolds. | — |
| 32 | MicroCures Pioneering cell migration therapeutics for tissue repair and regenerative medicine | $10M | 13 mo ago | 7 | 2011 | — | 40 patents Ocular regenerative therapeutics targeting fidgetin‑like 2 for wound healing and neurotrophic keratitis | 4 launchs |
| 33 | Eden Medical Developer of medical device for the treatment of wounds | $8M | 21 mo ago | — | 2000 | — | — | — |
| 34 | BRIJ Medical Provider of a medical devices for post-surgical and trauma incision care | $6M | 5 mo ago | — | 2016 | — | — | 1 launch |
| 35 | GelSana Developer of novel hydrogels for wound healing | $4M | 11 mo ago | 2 | 2020 | — | — | 1 partnership |
| 36 | NeXtGen Biologics Regenerative medicine company pioneering axolotl-derived technology for advanced wound healing | $4M | 10 mo ago | 10 | 2014 | — | — | 2 partnerships |
| 37 | Keraplast Technologies Ethically sourced keratin ingredients for personal care, nutraceutical, and wound care | $4M | 29 mo ago | 15 | 1997 | — | — | — |
| 38 | Lynch Biologics Developer of regenerative medicines for orthopaedic, periodontal and oral treatments | $4M | 29 mo ago | 9 | 2015 | — | — | — |
| 39 | SanaHeal Provider of bioadhesive tape for healthcare | $3M | 20 mo ago | 8 | 2021 | — | 2 patents Dermatological transdermal drug delivery films for skin treatment | — |
| 40 | Glycologix Developer of biopolymers for the protection and repair of soft tissues | $3M | 6 mo ago | 7 | 2016 | — | 25 patents Sulfated glycosaminoglycan biomaterials for proteoglycan-mimetic tissue engineering and regenerative therapeutics | — |
| 41 | inSoma Bio Provider of protein-based biomaterials for tissue engineering and regenerative medicine | $3M | 6 mo ago | 6 | 2018 | — | — | — |
| 42 | SelSym Developer of therapeutics for hemostasis and wound healing | $3M | 9 mo ago | 5 | 2019 | — | — | — |
| 43 | BioStem Technologies Provider of placental-based amniotic tissue products | $2M | 31 mo ago | 10 | 2006 | 9 signals ▼36% Earnings · Leadership · Acquisition | 7 patents Regenerative biomaterials from human umbilical cord and placental tissue for therapeutic applications | — |
| 44 | ECI Therapeutics Developer of therapeutics to treat multiple diseases | $2M | 25 mo ago | — | 2023 | — | — | — |
| 45 | Aethl Bio Developer of medical products for treating chronic skin wound conditions | $2M | 11 mo ago | — | 2025 | — | — | 1 job opening · 1 partnership |
| 46 | SanuWave Developer of Noninvasive devices, and biologics for wound healing | $1M | 24 mo ago | 38 38 → 80 (+111%) | 2005 | 9 signals ▼50% Earnings · Contracts | 191 patents Catheter-based shock wave therapy devices for vascular and tissue medical treatments | — |
| 47 | Comfort Release Provider of adhesive bandages & dressing products for skin wound management | $1M | 21 mo ago | — | 2010 | — | — | — |
| 48 | Numobag Developer of topical hyperbaric oxygen therapy for wound healing | $950K | 22 mo ago | 4 | 2006 | — | — | — |
| 49 | Mussel Polymers Manufacturer of adhesive solutions for multiple applications | $500K | 5 mo ago | 13 | 2019 | — | 41 patents Catechol‑based polymer adhesives and coatings for dental, wet‑bonding, and high‑performance fiber applications | — |
| 50 | Plakous Therapeutics Developer of regenerative therapies from the placenta | $310K | 16 mo ago | 6 | 2016 | — | — | — |
Top 12 Wound Care companies in United States
#1
Series B · New York City, New York · founded 2010 · 73 employees$81.7Mraised▾
Developer of hemostatic products for wound care. The company offers VETIGEL Hemostatic Gel(a prescription hemostatic gel kit for animal use only. It can stop moderate to severe bleeds in animals), and TRAUMAGEL a hemostatic device for temporary use to control external traumatic bleeding not amenable to tourniquet application.
- Apr 2026Series B$5M
- Nov 2025Series B$6.7M
- Apr 2024Series B$25M
- Aug 2023Series A$17.2M
#2
Series B · Plymouth, Minnesota · founded 2019 · 16 employees$23.1Mraised▾
Developer of surgical mesh for wound management. The products developed are FDA-approved MIRODERM (derived from the porcine liver) and MIROMESH (non-crosslinked acellular surgical mesh) that uses perfusion decellularization technology. It is used to treat wounds, ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, tunneled and undermined wounds, trauma wounds, drainage wounds, and surgical wounds.
- Jun 2025Series B$6.4M
- Jan 2023Series B$15.3M
- Mar 2021Series A$5M
- Nov 2020Seed$2.8M
#3
Series C · Madison, Wisconsin · founded 2010 · 35 employees$34.3Mraised▾
Provider of nanotech-based wound care products. The company has developed technologies for embedding bioactive molecules in wound dressings and surgical implants. The products are based on the Microlyte Matrix technology platform. The company also offers antibacterial, anti-biofilm, and analgesic wound dressings.
- Jan 2026Series C—
- Jan 2024Convertible Debt$10M
- Dec 2023Series B$3.5M
- May 2023Series B$2.5M
#4
Series A · Sarasota, Florida · founded 2005 · 22 employees$13Mraised▾
Discovering and developing solutions for closing chronic wounds and preventing their recurrence. Its product includes omeza omega-3 oil that helps moisturize and exfoliate the skin while improving skin elasticity and supporting healing, omeza lidocaine lavage for pain relief, and omeza collagen matrix among others.
- Apr 2026Series A$8.5M
- Dec 2024Series A$906.3K
- Mar 2021Series A$5M
- Aug 2019Series A$7M
#5
Public · Gaithersburg, Maryland · founded 2001 · 10 employees$64.6Mraised▾
Developer of regenerative products for wound care. The company focuses on regenerative therapies to primarily address the areas of wound care, inflammation, and angiogenesis. Its proprietary technology Aurix is a biodynamic hematogel that is an auto platelet and plasma therapy system. It has been approved by the FDA for use in the management of wounds and ulcers of all types and severities.
- Jul 2025Post IPO$791.4K
- Sep 2024Post IPO$849.1K
- May 2024Post IPO$650.9K
- Dec 2023Post IPO$962.5K
#6
Series A · Zionsville, Indiana · founded 2014 · 4 employees$10.5Mraised▾
Developer of collagen polymers for tissue regeneration. It offers Collymer a polymerizable scaffold-forming collagen that supports tissue restoration and regeneration. It is used in cartilage replacement, vascular grafts, and heart valve replacement, and others.
- Jan 2026Series A$3M
- Oct 2024Grant (prize money)$500K
- Mar 2023Series A$6M
- Nov 2022Series A$4.5M
#7
Seed · Marietta, Georgia · founded 2016$5.6Mraised▾
Provider of a medical devices for post-surgical and trauma incision care. The company offers BRIJJIT is a force-modulating tissue bridge to relieve tension around incisions, supporting beautiful healing and reducing wound complications.
- Jan 2026Seed—
- Feb 2025Seed$1.2M
- Dec 2023Seed$5.6M
#8
Seed · Beverly, Massachusetts · founded 2016 · 7 employees$3.2Mraised▾
Developer of biopolymers for the protection and repair of soft tissues. The company is developing a non-systemic, highly cross-linked chondroitin sulfate (CS) based biopolymer platform for soft tissue protection and repair which is focused on a broad range of medical needs such as interstitial cystitis, dry eye, surgical adhesion prevention, osteoarthritis, disk disease, and wound repair.
- Dec 2025Seed$800K
- Dec 2025Conventional Debt—
- Apr 2024Seed$1.5M
- May 2023Seed$1.8M
#9
Seed · Durham, North Carolina · founded 2018 · 6 employees$2.8Mraised▾
Provider of protein-based biomaterials for tissue engineering and regenerative medicine. The company offers genetically engineer protein-based materials that can mimic the naturally found elastin found in extracellular. The company's proprietary protein biomatrices known as Fractomers contain bio-active sequences that are thermo-responsive.
- Nov 2025Grant (prize money)$2M
- Sep 2025Seed$1.9M
- Sep 2024Grant (prize money)$294K
- Aug 2024Grant (prize money)$296.2K
#10
Funding Raised · The Bronx, New York · founded 2011 · 7 employees$9.7Mraised▾
Pioneering cell migration therapeutics for tissue repair and regenerative medicine. This company is at the forefront of tissue repair and regenerative medicine, leveraging a first-of-its-kind therapeutic platform that precisely controls cell movement. This innovative approach enhances the body's natural healing processes through local modulation of cell motility, offering potential therapeutic benefits for various medical applications. The company focuses on developing siRNA therapeutics to accelerate and improve tissue and nerve regeneration. Their pipeline includes programs targeting corneal, nerve, and dermal repair, with follow-on programs in burn healing, central nerve regeneration, cardiac repair, cancer metastases, and fibrosis. The company's technology directs and enhances the body’s inherent tissue repair processes through local, non-systemic, and temporary modulation of cell motility. With a strong intellectual property estate, the company is positioned as a leader in therapeutic modulation of cell movement, offering partnering and licensing opportunities.
- May 2025Grant (prize money)$502.9K
- Apr 2025Grant (prize money)$1.8M
- Jan 2025Grant (prize money)$1.7M
- Sep 2023Grant (prize money)$380K
#11
Series A · San Diego, California · founded 2014 · 15 employees$20.2Mraised▾
Developer of regenerative biomaterials for wounds. The company uses Microporous Annealed Particle technology that enables the creation of fully synthetic and precision-engineered injectable materials that can modulate a patient's own immune cells to drive regenerative biological responses which can be used to treat various diseases.
- Feb 2025Grant (prize money)$2.5M
- Mar 2024Series A$16.3M
- Sep 2020Grant (prize money)$256K
- Jun 2020Series A$3.8M
#12
Public · Canton, Massachusetts · founded 1985 · 856 employees$30Mraised▾
Regenerative tissue innovations for advanced wound care and surgical solutions. We are dedicated to empowering healing through regenerative medicine. Our focus lies in delivering clinicians a comprehensive range of regenerative tissue innovations and essential services. We specialize in advanced wound care and surgical & sports medicine solutions. We are committed to elevating the standard of care by providing transformative solutions. Our offerings include products like PuraPly and Affinity, alongside patient and provider support programs. We focus on innovation and regenerative solutions. We provide resources and support to healthcare professionals, ensuring they have access to the most advanced regenerative solutions available. We are committed to corporate social responsibility, ethics, and quality systems.
- Nov 2024Post IPO$130M
- May 2017Conventional Debt$20M
- Apr 2016Series C$30M
- Jan 2009Grant (prize money)$7.4M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Wound Care coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Medical Devices is moving in the United States
A read on the academic research around Medical Devices — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,830 United States-affiliated papers.
- Johns Hopkins University74
- United States Food and Drug Administration59
- Harvard University54
- Center for Devices and Radiological Health53
- Design Intelligence36
- Biocompatible material2→9
- Robotics7→13
- Health care1→6
- Tissue engineering1→5
- Automation1→5
- Health care2→24
- MEDLINE1→21
- Quality (philosophy)3→15
- Robotic surgery18→29
- Product (mathematics)5→16
- MEDLINE1→36
- Robotic surgery7→24
- Patient safety19→32
- Key (lock)6→19
- Quality (philosophy)10→20
Where medical devices is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing medical devices patents in the United States
United States medical devices patent filing is accelerating — 666,693 filings from 8,000 assignees (2016–2025), led by Covidien, Boston Scient Scimed, Medtronic; annual filings 63466→63610.
- Covidien29351
- Boston Scient Scimed24769
- Medtronic22424
- Becton Dickinson18264
- Procter & Gamble16198
- Ethicon ENDO Surgery13747
- Kimberly Clark12458
- Ethicon11765
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.